Skip to main content
OpenTrials
Completed

NCT Number: NCT00694707

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Forest Investigative Site, Vijaywada, ANDH PRAD, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18 to 60 years of age.
  • Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or undifferentiated type) based on a Structured Clinical Interview for DSM-IV (SCID).
  • Total Positive and Negative Syndrome Scale (PANSS) score ≥ 80 and ≤ 120.
  • Diagnosis of schizophrenia for at least 1 year.

Exclusion criteria

  • Abnormalities on physical examination or abnormal vital signs, electrocardiogram, or clinical laboratory values.
  • First episode of psychosis.

Treatment and study plan

Placebo

Drug

Placebo was supplied in capsules.

Cariprazine

Drug

Cariprazine was supplied in capsules

Other names: RGH-188

Risperidone

Drug

Risperidone was supplied in capsules

Other names: Risperdal

Primary outcomes

  1. Change From Baseline to Week 6 in the PANSS Total Score

    Time frame: Baseline to Week 6

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, blunted affect, emotional withdrawal); and 16 assess general psychopathology (eg, poor attention, active social avoidance). Each item is scored on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderately severe, 6 = severe, and 7 = extreme). The PANSS total score can range from 30 to 210. A higher score indicates worse symptoms. A negative change score indicates improvement.

Secondary outcomes

  1. Change From Baseline to Week 6 in the CGI-S Score

    Time frame: Baseline to Week 6

    The Clinical Global Impressions-Severity (CGI-S) scale is a 7-point scale that measures the overall severity of the illness compared with the severity of illness in other patients the Investigator has observed. The Investigator assesses the severity of the patient's illness as one of the following: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patients. The CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change score indicates improvement.

Sponsors and collaborators

Lead sponsor

Forest Laboratories

Industry

Collaborators

  • Gedeon Richter Ltd.

Registry information

Official study title

Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Jun 10, 2008
Registry last updated
Jun 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.